Literature DB >> 25790541

Is there any impact of PET/CT on radiotherapy planning in rectal cancer patients undergoing preoperative IMRT?

Diclehan Kiliç, Serap Çatli, Şükran Ülger, Lütfiye Özlem Kapucu.   

Abstract

BACKGROUND/AIM: To investigate the effect of positron emission tomography-computed tomography (PET/CT)-based contouring on dosimetric parameters in rectal cancer patients undergoing preoperative intensity-modulated radiation therapy (IMRT).
MATERIALS AND METHODS: Preoperative radiation therapy plans with conformal radiotherapy (CRT) or IMRT were created and examined according to the CT- and PET/CT-based contouring of 20 rectal cancer patients, retrospectively.
RESULTS: The target volumes delineated with PET/CT were significantlylarger than the volumes created by CT (P= 0.043). Dose delivered to 98% of the planning target volume was high in IMRT planning contouring with CT and PET/CT compared with CRT planning, but the difference was not statistically significant (P = 0.056). Percent volumes receiving 105% of dose and 110% of dose were low in IMRT planning when compared with CRT (P < 0.0001 and P = 0.044, respectively). The volumes receiving 45 Gy for the small intestine, femur heads, and bladder and the maximum dose received by the bladder were significantly lower in IMRT.
CONCLUSION: We showed that the target volumes created with PET/CT are significantly larger than the target volumes created with CT and that IMRT provides lower radiation exposure to the tumor-free tissues compared to the CRT planning. The dosimetric results primarily favor IMRT planning in rectal cancer patients and consequently present the significant alteration in target volumes.

Entities:  

Mesh:

Year:  2015        PMID: 25790541     DOI: 10.3906/sag-1312-149

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  1 in total

1.  Small bowel protection in IMRT for rectal cancer : A dosimetric study on supine vs. prone position.

Authors:  Julia Koeck; Katharina Kromer; Frank Lohr; Tobias Baack; Kerstin Siebenlist; Sabine Mai; Sylvia Büttner; Jens Fleckenstein; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2017-02-20       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.